Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclin b1 peptide
- Development stage
- Unknown
- Lead developer
- Baylor Research Institute
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Peptides, Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intradermal, Subcutaneous, Intravenous
01
Overview
Cyclin b1 peptide is a synthetic peptide derived from the cell cycle regulator protein cyclin B1. It is primarily used as an immunotherapeutic agent in cancer research and clinical trials, often as part of a dendritic cell vaccine platform. Cyclin B1 is overexpressed in various tumor cells and plays a critical role in regulating the G2/M transition during cell division. By pulsing autologous dendritic cells with cyclin B1 peptides, these vaccines aim to stimulate cytotoxic T lymphocyte responses against tumor cells expressing high levels of cyclin B1, thereby promoting anti-tumor immunity[1][2][8]. The mechanism of action involves presenting the cyclin B1 epitope to T-cells via major histocompatibility complex (MHC) molecules on dendritic cells, leading to targeted immune-mediated destruction of cancer cells.
- Other names
- cyclin B1-derived peptideCCNB1 peptideCCNB-1 peptideCCNB 1 peptide
02
Targets
CCNB1 (Cyclin B1)γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on cyclin b1 peptide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclin b1 peptide.